Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

@article{Schmitz2012PhaseIS,
  title={Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).},
  author={Sandra Schmitz and M-C Kaminsky-Forrett and Stephanie L Henry and Sylvie Zanetta and Lionnel Geoffrois and Emmanuelle Bompas and Anne Moxhon and Lionel Mignion and Jo{\"e}l Guigay and Laurent Knoops and Marc Hamoir and Jean-Pascal Machiels},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 8},
  pages={2153-61}
}
BACKGROUND Preclinical studies suggest that insulin-like growth factor-1 receptor (IGF-1R) blockage could be a promising therapeutic target in squamous cell carcinoma of the head and neck (SCCHN). Therefore, we investigated the efficacy and toxicity of figitumumab, an anti-IGF-1R monoclonal antibody, in palliative SCCHN. PATIENTS AND METHODS Patients with palliative SCCHN progressing after platinum-based therapy were treated with figitumumab i.v. 20 mg/kg, every 3 weeks. The primary end point… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
31 Extracted Citations
40 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 31 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 40 references

Similar Papers

Loading similar papers…